https://www.selleckchem.com/products/amg510.html
Patients with COVID-19 acute respiratory distress syndrome (ARDS) have been shown to have high sedation requirements. The purpose of this study was to compare sedative use between patients with COVID-19 ARDS and non-COVID-19 ARDS. This was a retrospective study of patients with COVID-19 ARDS compared with historical controls of non-COVID-19 ARDS who were admitted to 2 hospitals from March 1, 2020, to April 30, 2020, and April 1, 2018, to December 31, 2019, respectively. The primary outcome was median cumulative dose of propofol (µg/kg) a
Curtir
Comentario
Compartilhar
